Combo of targeted and immunotherapy may boost NSCLC treatment by overcoming immune resistance and enhancing anti-tumor activity Post author: Post published:February 15, 2024 Post category:uncategorized Researchers evaluated rational combination treatment regimens for advanced/metastatic non-small-cell lung cancer (NSCLC). You Might Also Like New clues to how food allergies trigger anaphylaxis August 7, 2025 Evosep Strengthens Leadership to Drive Scale-Up September 29, 2023 Global proteomics data sharing grows fast as ProteomeXchange scales up April 20, 2026